Prelude Therapeutics Inc (PRLD) SEC Filings & Earnings Calls

Early-stage clinical risk: PRT13722 is entering Phase 1; no efficacy data yet.

“Phase 1 study under its Investigational New Drug Application for PRT13722” · word for word

Reliance on pipeline: no approved products; all programs are preclinical or early clinical.

“This presentation concerns drugs that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration” · word for word

Clinical-stage company with no approved products; pipeline execution risk

“Company is a clinical-stage precision oncology company; all programs are in development.”

Going concern risk

“The Company has incurred operating losses and had an accumulated deficit of $707.4 million as of June 30, 2026.” · word for word

Dependence on Incyte option exercise

“If Incyte elects to not exercise its option to acquire the Program, all Transferred Assets would remain in the sole ownership and control of the Company.” · word for word

No product revenue

“The Company has no product revenue to date and devotes its efforts to research and development.” · word for word

No product revenue; reliance on partnership and equity financing

“To date, we have not recognized any revenue from product sales, and we do not expect to generate any revenue from the sale of products in the foreseeable future.” · word for word

Dilution from equity offering

“Subsequent to March 31, 2026, the Company sold 16,611,014 shares of its voting common stock at a price of $4.44 per share and pre-funded warrants to purchase up to 3,659,252 shares of its common stock at a price of $4.4399 per pre-funded warrant, resulting in gross proceeds of approximately $90.0 million.” · word for word

Clinical development risk for JAK2V617F and KAT6A programs

“The Phase 1 study of PRT12396 is an open-label, multi-center, safety and efficacy study. The primary endpoints of the study include safety, efficacy and PK profile.” · word for word

Early-stage pipeline with no approved products; reliance on clinical trial success.

“All programs are in preclinical or Phase 1 stages; no revenue from product sales.”

Dependence on partnership with Incyte for JAK2V617F program; option agreement may limit upside.

“The JAK2V617F inhibitor program is subject to an exclusive option agreement with Incyte.” · word for word

Dilution Risk

“On April 21, 2026, the Issuer completed an underwritten public offering of (i) 18,018,014 Shares, at a price of $4.44 per share, and (ii) pre-funded warrants to purchase up to 2,252,252 Shares, at a price of $4.4399 per warrant with an exercise price of $0.0001 per share (the "Offering").” · word for word

Dilution Risk

“On April 21, 2026, the Issuer completed an underwritten public offering of (i) 18,018,014 Shares, at a price of $4.44 per share, and (ii) pre-funded warrants to purchase up to 2,252,252 Shares, at a price of $4.4399 per warrant with an exercise price of $0.0001 per share (the "Offering").” · word for word

Dilution from public offering

“The Offering closed on April 21, 2026... 18,018,014 shares of common stock... at a price to the public of $4.44 per share.” · word for word

No revenue; clinical-stage company dependent on pipeline success.

“Clinical-stage precision oncology company; no revenue mentioned.”

Cash runway only into Q2 2027; need for future financing likely.

“Current cash runway expected into second quarter of 2027 with $106 million.” · word for word

No product revenue; history of losses

“We have never generated any product revenue and we do not know when, or if, we will generate any product revenue.” · word for word

Need for substantial additional capital

“We will require substantial additional funding to pursue our business objectives. If we are unable to raise capital when needed or on terms acceptable to us, we could be forced to delay, reduce or eliminate our research or drug development programs.” · word for word

Early-stage pipeline; high risk of clinical failure

“We are highly dependent on the success of our product candidates which are in early development. We have not completed successful late-stage pivotal clinical trials or obtained regulatory approval for any product candidate.” · word for word

Reliance on single source suppliers and third-party manufacturers

“We rely on third-party suppliers, including single source suppliers, to manufacture preclinical and clinical supplies of our product candidates.” · word for word

Intense competition from larger companies

“Many of the companies against which we are competing ... have significantly greater financial resources and expertise ... than we do.” · word for word

Preclinical stage; no clinical data yet; execution risk for IND filings.

“Programs in IND-enabling studies; no clinical data reported.”

Going Concern Uncertainty

“substantial doubt exists about our ability to continue as a going concern.” · word for word

Pipeline Setback

“On November 4, 2025 we announced that we decided to pause the clinical development of our SMARCA2 degrader program which is comprised of PRT3789 and PRT7732.” · word for word

No Product Revenue

“To date, we have not recognized any revenue from product sales, and we do not expect to generate any revenue in the foreseeable future.” · word for word